<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986297</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000654621</org_study_id>
    <secondary_id>SCCC-05509</secondary_id>
    <secondary_id>072009-061</secondary_id>
    <nct_id>NCT00986297</nct_id>
  </id_info>
  <brief_title>Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status</brief_title>
  <official_title>Phase 1 Study of Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-IV Non-Small Cell Lung Cancer and Poor Performance Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to&#xD;
      the tumor may kill more tumor cells and cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of specialized&#xD;
      radiation therapy in treating patients with stage II, stage III, stage IV, or recurrent&#xD;
      non-small cell lung cancer and poor performance status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To escalate the dose of accelerated hypofractionated image-guided conformal radiotherapy&#xD;
           to a potent tumoricidal dose without exceeding the maximum-tolerated dose in patients&#xD;
           with recurrent or stage II-IV non-small cell lung cancer and poor performance status.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate local regional tumor control and overall survival of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo accelerated hypofractionated image-guided conformal radiotherapy&#xD;
      once daily, 5 days a week, for 3 weeks (15 fractions). Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local regional tumor control</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>arm one</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IGRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiation therapy</intervention_name>
    <description>hypofractionated radiation therapy</description>
    <arm_group_label>arm one</arm_group_label>
    <other_name>IGRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage II-IV and/or recurrent disease&#xD;
&#xD;
               -  No small cell histology&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Tumor not amenable to surgical resection&#xD;
&#xD;
               -  Tumor not eligible for stereotactic body radiation therapy&#xD;
&#xD;
          -  No prior radiotherapy to the region of the study cancer that would result in overlap&#xD;
             of radiation therapy fields&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 2-4&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must agree to use effective contraception&#xD;
&#xD;
          -  Must complete all required pretreatment evaluations&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 1 week since prior chemotherapy or chemoradiation therapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy (including standard-fractionated&#xD;
             radiotherapy to the chest, chemotherapy, biological therapy, vaccine therapy, and&#xD;
             surgery) 1 week before, during, and for 1 week after completion of study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D. Timmerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>September 26, 2009</study_first_submitted>
  <study_first_submitted_qc>September 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

